EP1933864A4 - Antikörper als t-zell-rezeptor-mimics, herstellungsverfahren und ihre verwendungen - Google Patents

Antikörper als t-zell-rezeptor-mimics, herstellungsverfahren und ihre verwendungen

Info

Publication number
EP1933864A4
EP1933864A4 EP06814164A EP06814164A EP1933864A4 EP 1933864 A4 EP1933864 A4 EP 1933864A4 EP 06814164 A EP06814164 A EP 06814164A EP 06814164 A EP06814164 A EP 06814164A EP 1933864 A4 EP1933864 A4 EP 1933864A4
Authority
EP
European Patent Office
Prior art keywords
antibodies
production
methods
cell receptor
receptor mimics
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06814164A
Other languages
English (en)
French (fr)
Other versions
EP1933864A2 (de
Inventor
Jon A Weidanz
Vaughan Wittman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RECEPTOR LOGIC Ltd
Original Assignee
RECEPTOR LOGIC Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by RECEPTOR LOGIC Ltd filed Critical RECEPTOR LOGIC Ltd
Publication of EP1933864A2 publication Critical patent/EP1933864A2/de
Publication of EP1933864A4 publication Critical patent/EP1933864A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EP06814164A 2005-09-07 2006-09-07 Antikörper als t-zell-rezeptor-mimics, herstellungsverfahren und ihre verwendungen Withdrawn EP1933864A4 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US71462105P 2005-09-07 2005-09-07
US75154205P 2005-12-19 2005-12-19
US75273705P 2005-12-20 2005-12-20
US83827606P 2006-08-17 2006-08-17
PCT/US2006/034547 WO2007030451A2 (en) 2005-09-07 2006-09-07 Antibodies as t cell receptor mimics, methods of production and uses thereof

Publications (2)

Publication Number Publication Date
EP1933864A2 EP1933864A2 (de) 2008-06-25
EP1933864A4 true EP1933864A4 (de) 2009-12-16

Family

ID=37836380

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06814164A Withdrawn EP1933864A4 (de) 2005-09-07 2006-09-07 Antikörper als t-zell-rezeptor-mimics, herstellungsverfahren und ihre verwendungen

Country Status (5)

Country Link
EP (1) EP1933864A4 (de)
AU (1) AU2006289683A1 (de)
CA (1) CA2662798A1 (de)
IL (1) IL190014A0 (de)
WO (1) WO2007030451A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2656583A1 (en) * 2006-06-01 2007-12-13 Receptor Logic, Ltd. Antibodies as t cell receptor mimics, methods of production and uses thereof
WO2009108372A2 (en) * 2008-02-27 2009-09-03 Receptor Logic, Inc. Antibodies as t cell receptor mimics, methods of production and uses thereof
UA114108C2 (uk) 2012-07-10 2017-04-25 Борд Оф Ріджентс, Дзе Юніверсіті Оф Техас Сістем Моноклональне антитіло для застосування в діагностиці і терапії злоякісних пухлин і аутоімунного захворювання

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002014870A2 (en) * 2000-08-14 2002-02-21 Akzo Nobel N.V. Use of antibodies against specific mhc-peptide complexes
WO2003095486A1 (fr) * 2002-05-07 2003-11-20 Pierre Fabre Medicament UTILISATION DE PEPTIDE DERIVE DE LA SOUS-UNITE β DE L'HCG POUR GENERER UNE REPONSE DE TYPE CTL ANTITUMORALE
WO2005116072A2 (en) * 2004-05-27 2005-12-08 Weidanz Jon A Antibodies as t cell receptor mimics, methods of production and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE183514T1 (de) * 1992-05-26 1999-09-15 Univ Leiden Peptide des menschlichen proteins p53 zum gebrauch in menschlichen-zytotoxischen-t-zell- antwort-induzierenden kompositionen sowie menschliche p53-protein-spezifische t-lymphocyten
US5801005A (en) * 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US5968513A (en) * 1996-06-24 1999-10-19 University Of Maryland Biotechnology Institute Method of promoting hematopoiesis using derivatives of human chorionic gonadotropin
US20040191260A1 (en) * 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
EP1356048A2 (de) * 2000-12-04 2003-10-29 Argonex Pharmaceuticals Zytotoxisch t-lymphozyte induzierende immunogene zur krebsvorbeugung,behandlung, und diagnose
CA2476625A1 (en) * 2002-02-20 2003-08-28 Dyax Corp. Mhc-peptide complex binding ligands
WO2004101607A2 (en) * 2003-05-13 2004-11-25 Hildebrand William H Comparative ligand mapping from mhc class i positive cells

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002014870A2 (en) * 2000-08-14 2002-02-21 Akzo Nobel N.V. Use of antibodies against specific mhc-peptide complexes
WO2003095486A1 (fr) * 2002-05-07 2003-11-20 Pierre Fabre Medicament UTILISATION DE PEPTIDE DERIVE DE LA SOUS-UNITE β DE L'HCG POUR GENERER UNE REPONSE DE TYPE CTL ANTITUMORALE
WO2005116072A2 (en) * 2004-05-27 2005-12-08 Weidanz Jon A Antibodies as t cell receptor mimics, methods of production and uses thereof

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
AHARONI R ET AL: "Immunomodulation of experimental allergic encephalomyelitis by antibodies to the antigen-Ia complex", NATURE, NATURE PUBLISHING GROUP, LONDON, UK, vol. 351, no. 6322, 9 May 1991 (1991-05-09), pages 147 - 150, XP002514757, ISSN: 0028-0836 *
DANGLES V ET AL: "Tumor-associated antigen human chorionic gonadotropin beta contains numerous antigenic determinants recognized by in vitro-induced CD8+ and CD4+ T lymphocytes", CANCER IMMUNOLOGY AND IMMUNOTHERAPY, SPRINGER-VERLAG, BERLIN, DE, vol. 50, no. 12, 1 February 2002 (2002-02-01), pages 673 - 681, XP002236556, ISSN: 0340-7004 *
NEETHLING F A ET AL: "Assessing vaccine potency using TCRmimic antibodies", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 26, no. 25, 13 June 2008 (2008-06-13), pages 3092 - 3102, XP022710591, ISSN: 0264-410X, [retrieved on 20080225] *
PORGADOR A ET AL: "LOCALIZATION, QUANTITATION, AND IN SITU DETECTION OF SPECIFIC PEPTIDE-MHC CLASS I COMPLEXES USING A MONOCLONAL ANNTIBODY", IMMUNITY, CELL PRESS, US, vol. 6, no. 6, 1 June 1997 (1997-06-01), pages 715 - 726, XP000991374, ISSN: 1074-7613 *
REAY P A ET AL: "Determination of the relationship between T cell responsiveness and the number of MHC-peptide complexes using specific monoclonal antibodies", JOURNAL OF IMMUNOLOGY, AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 164, no. 11, 1 June 2000 (2000-06-01), pages 5626 - 5634, XP002366691, ISSN: 0022-1767 *
REITER Y ET AL: "peptide-specific killing of antigen-presenting cells by a recombinant antibody-toxin fusion protein targeted to major histocompatibility complex/peptide class I complexes with T cell receptor-like specificity", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 94, 1 April 1997 (1997-04-01), pages 4631 - 4636, XP002967291, ISSN: 0027-8424 *
WITTMAN VAUGHAN P ET AL: "Antibody targeting to a class I MHC-peptide epitope promotes tumor cell death", JOURNAL OF IMMUNOLOGY, AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 177, no. 6, 1 September 2006 (2006-09-01), pages 4187 - 4195, XP002514758, ISSN: 0022-1767 *

Also Published As

Publication number Publication date
EP1933864A2 (de) 2008-06-25
AU2006289683A1 (en) 2007-03-15
WO2007030451A3 (en) 2009-04-16
CA2662798A1 (en) 2007-03-15
WO2007030451A2 (en) 2007-03-15
IL190014A0 (en) 2008-08-07

Similar Documents

Publication Publication Date Title
IL179427A0 (en) Antibodies as t cell receptor mimics, methods of production and uses thereof
IL195470A0 (en) Antibodies as t cell receptor mimics, methods of production and uses thereof
HRP20190220T1 (hr) Anti-il-23 protutijela, pripravci, postupci i upotrebe
HUS1800021I1 (hu) Humán anti-Il-23 ellenanyagok, készítmények, eljárások és alkalmazások
HK1248523A1 (zh) 用電穿孔向細胞負載抗原
IL190472A (en) Glyphican Antibody 3 Methods for their preparation and use
EP1857126A4 (de) Gezüchtete zellplatte, herstellungsverfahren und anwendungsverfahren dafür
EP1988152A4 (de) Zellkulturkonstrukt, zellkulturbehälter, konstrukt mit sphäroid, behälter mit sphäroid und verfahren zur herstellung davon
HUE037580T2 (hu) Eszközök és eljárások ellenanyag-termelõ sejtek stabilitásának befolyásolására
EP1743025A4 (de) Herstellungsverfahren für regulator-t-zellen und deren verwendung
DE602006006377D1 (de) Brennstoffzellenseparator und seine Herstellungsmethode
EP2262834A4 (de) Antikörper als t-zellen-rezeptor-mimetika, herstellungsverfahren und ihre verwendungen
IL190014A0 (en) Antibodies as t cell receptor mimics, methods of production and uses thereof
GB0600991D0 (en) Assays, antibodies and uses thereof
GB0521718D0 (en) Assays, antibodies and uses thereof
GB0508701D0 (en) Assays, antibodies and uses thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080404

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

R17D Deferred search report published (corrected)

Effective date: 20090416

RIC1 Information provided on ipc code assigned before grant

Ipc: C07H 21/02 20060101ALI20090427BHEP

Ipc: A61B 5/055 20060101ALI20090427BHEP

Ipc: G01N 33/574 20060101ALI20090427BHEP

Ipc: C07K 16/00 20060101ALI20090427BHEP

Ipc: C07K 5/10 20060101ALI20090427BHEP

Ipc: A61K 39/00 20060101AFI20090427BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20091112

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/574 20060101ALI20091106BHEP

Ipc: C07K 16/32 20060101ALI20091106BHEP

Ipc: C07K 16/30 20060101ALI20091106BHEP

Ipc: C07K 16/28 20060101ALI20091106BHEP

Ipc: C07K 16/26 20060101ALI20091106BHEP

Ipc: C07K 16/00 20060101ALI20091106BHEP

Ipc: C07H 21/02 20060101ALI20091106BHEP

Ipc: C07K 5/10 20060101ALI20091106BHEP

Ipc: A61K 39/00 20060101ALI20091106BHEP

Ipc: A61B 5/055 20060101AFI20091106BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100112